Sunshine Biopharma Q1 2024 revenue up 54% to $7.54M; net loss narrows to $1.28M

Sunshine Biopharma Inc.

2024-Q1 EPS reported -$2.00 revenue$7,541,046

Q1 2024 revenue of $7,541,046, a 54% increase from $4,894,053 in Q1 2023.
Net loss of $(1,283,801) improved from $(1,702,430) in the prior-year quarter.
Gross profit rose to $2,354,337 from $1,828,122, driven by new product launches.
In February 2024, completed public offering for gross proceeds of ~$10 million.
Growth attributed to expanded sales efforts by subsidiary Nora Pharma Inc.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.